



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

**Public Summary**

<b>Summary for ARTG Entry:</b>	326211	Mega B Complex
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Herbs of Gold Pty Ltd	
<b>Postal Address</b>	PO Box 3143, KIRRAWEE, NSW, 2232 Australia	
<b>ARTG Start Date</b>	13/11/2019	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

**Conditions**

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

**Products**

**1 . Mega B Complex**

Product Type	Single Medicine Product	Effective Date	13/11/2019
--------------	-------------------------	----------------	------------

**Permitted Indications**

- Helps convert (state food) into energy
- Maintain/support energy production
- Maintain/support general health and wellbeing
- Aid/assist healthy red blood cell production
- Maintain/support red blood cell health
- Maintain/support blood health
- Helps maintain/support haemoglobin formation/synthesis
- Maintain/support cardiovascular system health
- Aid/assist/helps glucose/sugar/carbohydrate metabolism
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
- Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)
- Support healthy stress response in the body
- Maintain/support cognitive function/mental function
- Maintain/support brain function
- Maintain/support brain health
- Aid/assist/helps synthesis of neurotransmitters
- Maintain/support nervous system health
- Maintain/support nervous system function
- Maintains/support healthy foetal development

Public Summary



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

Maintain/support skin health

**Indication Requirements**

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to serious cardiovascular conditions.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

If directed to women, Label statement: Advise your doctor of any medicine you take during pregnancy, particularly in your first trimester.

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>Biotin</b>	<b>100 microgram</b>
<b>calcium folinate</b>	<b>537.5 microgram</b>
Equivalent: folic acid	400 microgram
<b>calcium pantothenate</b>	<b>75 mg</b>
Equivalent: pantothenic acid	68.18 mg
<b>choline bitartrate</b>	<b>50 mg</b>
<b>cyanocobalamin</b>	<b>500 microgram</b>
<b>inositol</b>	<b>50 mg</b>
<b>nicotinamide</b>	<b>100 mg</b>
<b>nicotinic acid</b>	<b>10 mg</b>
<b>pyridoxine hydrochloride</b>	<b>100 mg</b>
Equivalent: pyridoxine	82.27 mg
<b>riboflavine</b>	<b>100 mg</b>
<b>thiamine hydrochloride</b>	<b>100 mg</b>
Equivalent: thiamine	89.19 mg

**Other Ingredients (Excipients)**

- colloidal anhydrous silica
- disodium edetate
- Flavour
- gellan gum
- hypromellose

Public Summary



**Australian Government**

**Department of Health**  
Therapeutic Goods Administration

potable water

potassium acetate

silicon dioxide

stearic acid

---

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary